DERMAFLOW SIGNS JOINT VENTURE AGREEMENT
Moorestown NJ, 7-March 2022: DermaFlow – a US based healthcare technology company - has signed a Joint Venture agreement with iiV Health Solutions of Mumbai, India, to commercialize the company’s flagship product DermaVasc™, a non-invasive point of care/ Self testing device for the measurement of capillary blood flow in the lower limbs. The joint venture company, iiVH DermaFlow Health Solutions Private Ltd., will focus its efforts in India and surrounding countries, including the Gulf States.
DermaVasc features the DermaFlow proprietary technology, Perichek™,- a product of Israeli R&D - combined with a blood flow stimulating device. The combination has been shown to detect early changes in peripheral capillary blood flow in the lower limbs – a feature of peripheral artery disease – even before the onset of symptoms.
Read More
PAD the Silent Killer and How DermaVasc™ Makes a Difference
“In the specific market we are addressing today, the peripheral vascular market, we look for early signs of deterioration in the blood flow in the lower limbs, which can lead to PAD (Peripheral Arterial Disease). About 50% of PAD subjects are asymptomatic, meaning they have no symptoms and there is a huge number of people that are not aware that their peripheral vascular condition is deteriorating. This is not being routinely screened nor monitored today and it needs to be. All of this is part of the Dermaflow and DermaVasc™ mission.”
Read More
The most significant trends impacting treatment of the #1 killer and who's killing it!
Early diagnosis, less invasive treatments, and remote rehab standout as the most significant areas in which strides are being made in vascular health as we head into 2021.
Why do we care about vascular health?
For starters, COVID 19 has shed light on the poor vascular health around the world, with the majority of serious complications being experienced by those suffering from vascular diseases such as Cardiovascular Disease, Peripheral Artery Disease (PAD), which is a narrowing of the blood vessels in mainly the legs due to plaque build-up much like it is with CVD in the heart, and diabetes.
Read More
Innovation Spotlight: DermaFlow | New Early Detection Technology for Peripheral Artery Disease
Interview by Kym McNicholas, The Way To My Heart
As part of the ongoing Vascular Innovation Series in conjunction with The Way To My Heart, journalist Kym McNicholas interviewed DermaFlow CEO and Board Member, Irene Jaffe, Ph.D. DermaFlow develops a non-invasive proprietary technology to monitor and stimulate the peripheral blood flow. Dermiflow’s Perivasc and DermVasc are currently limited to investigative use.
Read More
Professor David Armstrong, Vascular Expert, Unites with DermaFlow
[October 25, 2020] Dermaflow is privileged to announce the signing of a collaboration agreement between the company and Professor David Armstrong, PhD, DPM, Professor of Clinical Surgery at the Keck School of Medicine, University of Southern California.
Professor Armstrong, as a Key Opinion Leader, will advise Dermaflow on possible home and clinical applications and product forms of the company’s proprietary technology, in the vascular field, as well as work with us on partnering strategy regarding both clinical and business collaborations.
Read More
